Small molecule inhibitors of aurora kinases are currently being investigated in oncology clinical trials. The long-term effects of these inhibitors on proliferating euploid cells have not been adequately studied. We examined the effect of the reversible pan-aurora kinase inhibitor VX-680 on p53-competent human euploid cells. Circumscribed treatment with VX-680 blocked cytokinesis and arrested cells in G1 or a G1-like status. Approximately 70% of proliferatively arrested cells had 4N DNA content and abnormal nuclei. The remaining 30% of cells possessed 2N DNA content and normal nuclei. The proliferative arrest was not due to the activation of the tumor suppressor Rb and was instead associated with rapid induction of the p53–p21 pathway and p16. The induction was particularly evident in cells with nuclear abnormalities but was independent of activation of the DNA damage response. All of these effects were correlated with the potent inhibition of aurora kinase B. After release from VX-680, the cells with normal nuclei robustly resumed proliferation whereas the cells with abnormal nuclei underwent senescence. Irrespective of their nuclear morphology or DNA content, cells pre-treated with VX-680 failed to grow in soft agar or form tumors in mice. Our findings indicate that an intermittent treatment strategy might minimize the on-target side effects of Aurora Kinase B (AURKB) inhibitory therapies. The strategy allows a significant fraction of dividing normal cells to resume proliferation.

LG157 is a recently identified small-molecule inhibitor of mitotic kinesin-like protein 2 (MKLP2), an overlooked oncology target. This study aims to explore the drug developability of LG157, by assessing its druglike properties, determining plasma drug exposure in various oral formulations, and exploring the self-emulsifying drug delivery system (SEDDS). Solubility of LG157 ranges from 175 to 228 μM across pH 1.0 to 13.0, with a LogD of 2.41 at pH 7.4. It showed a high protein binding rate of 92.58% in mouse plasma and 90.30% in human serum. The bioavailability radar plot aligns with experimental data (69-85%), indicating good bioavailability. In line with the computation prediction, preclinical formulation studies in mice reveal that all five formulations tested offer decent plasma LG157 exposure, with the highest level of LG157 exposure in the PEG300-based formulation. Subsequent tissue distribution studies in rats indicated that the compound is widely distributed with the highest concentration of LG157 in the liver and the lowest level in the brain. The optimal SEDDS formulation, SEDDS-F14, consists of 65% Oleic acid, 26.25% Tween 20, and 8.75% PEG400 as oil, surfactant, and co-surfactant, respectively. SEDDS optimization, based on the central composite design, has achieved the maximum loading of 188.7 mg/mL for LG157. These findings support the developability of LG157 and encourage continued exploration and refinement of formulations for improved therapeutic efficacy.